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Abstract
The overexpression of AXL receptor tyrosine kinase is a frequent finding that has been associated with poor prognosis
in esophageal adenocarcinoma (EAC). As themajority of EAC are intrinsically resistant to DNA-damaging therapies, an
alternative therapeutic approach based on the activation of death receptors may bewarranted. Tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) has been evaluated in clinical trials and found promising as anticancer agent
with mild side effects; unfortunately, resistance to TRAIL remains a major clinical problem. Herein, we explored the
role of AXL in TRAIL resistance and elucidated the underlying mechanism. Overexpression of AXL in OE33 and OE19
cells promoted cell survival and attenuated TRAIL-induced cellular and molecular markers of apoptosis. In contrast,
knockdown of endogenous AXL sensitized FLO-1 cells to TRAIL. The mechanism by which AXL regulates TRAIL
resistance was examined. Protein and mRNA expression of DR4 and DR5 death receptors was not downregulated by
AXL. In addition, the possible involvement of FLICE-inhibitory protein (FLIP) in regulating the interaction of caspase-8
with Fas-associated death domain protein (FADD) was excluded, as AXL did not enhance FLIP expression or FLIP/
FADD association. Alternatively, protein association of AXLwith DR5, independent of TRAIL, was confirmed, suggest-
ing that AXL could regulate DR5 receptor activity. The AXL/DR5 association had no negative effect on TRAIL-induced
interaction with FADD. However, the AXL/DR5 interaction blocked the recruitment of caspase-8 to the death-inducing
signal complex (DISC). Collectively, our findings uncover a novel mechanism of TRAIL resistance mediated by AXL
through regulation of the DISC and provide strong evidence that AXL could be exploited as a therapeutic target to
circumvent TRAIL resistance.
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Introduction
Esophageal cancer, which includes squamous cell carcinoma and ade-
nocarcinoma, is an aggressive neoplasm and a major cause of cancer-
related deaths in the world [1]. Projections of approximately 14,000
new cases of esophageal cancer, most of which are esophageal adeno-
carcinoma (EAC), occur per year in the United States [2,3]. Since the
majority of patients with EAC present with advanced disease, 5-year
relative survival rates are estimated as low as 14% [4,5]. This clearly
indicates the ineffectiveness of the current treatment regimens and
highlights that the intrinsic resistance to therapy is a hallmark of EAC.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
induces apoptosis upon binding to DR4 or DR5 death receptors [6].
TRAIL-induced activation of death receptors leads to the formation
of death-inducing signaling complex (DISC), which consists of death
receptor, Fas-associated death domain protein (FADD), and caspase-8.
The autocatalytic activation of caspase-8 induced by DISC-mediated
proximity leads to direct activation of caspase-3 and apoptosis (extrinsic
pathway) in type I cells [7]. Additionally, caspase-8 cleaves Bid and
activates the intrinsic mitochondrial apoptosis pathway in type II cells
[8,9]. Because of the unique feature of TRAIL that selectively induces
apoptosis in malignant cells and mostly sparing normal cells, several
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anticancer therapeutic strategies have been developed [10,11]. Re-
combinant proteins, such as TRAIL, or agonistic human monoclonal
antibodies against DR4 or DR5 death receptors are frequently used to
induce apoptosis of cancer cells [12,13]. Unfortunately, a significant
proportion of cancer cells are refractory to TRAIL-induced cytotoxicity,
even though they express functional death receptors. TRAIL resistance
can be mediated by several mechanisms, such as expression of FLICE-
inhibitory protein (FLIP), which is similar to caspase-8 but lacking the
enzymatic activity. FLIP competes with caspase-8 for binding FADD,
hence blocking TRAIL-induced apoptotic signaling cascade [14].
Moreover, TRAIL resistance can be modulated by expression of decoy
death receptors, mutations in the caspase-8 gene, and activity of AKT
and nuclear factor of kappa light polypeptide gene enhancer in B-cells
(NF-kB; reviewed in [15]).
AXL, a member of the TAM family of receptor tyrosine kinases,
was originally isolated from human leukemia cells and identified as a
transforming gene [16,17]. Overexpression of AXL in the presence of
its ligandGas6 stimulation has been implicated in cell growth,migration,
and survival through activation of AKT and mitogen-activated protein
kinases (MAPK) pathways in solid tumors [17–19]. Findings from re-
cent studies on non-small cell lung carcinoma indicated that increased
activation of AXL-induced acquired resistance to epidermal growth fac-
tor receptor (EGFR)-targeted therapy [20], whereas inhibition of AXL
promoted chemosensitivity and apoptosis [21]. A previous report in-
dicated that AXL was upregulated in the multistep esophageal carcino-
genesis and a marker of poor prognosis in EAC [22]. Recently, we
have shown frequent overexpression of AXL in EAC and demonstrated
that AXL promotes cisplatin resistance through regulation of c-ABL/p73
signaling [23].
The aim of this study was to investigate the role of AXL in TRAIL
resistance in EAC and elucidate the molecular mechanism that controls
this effect. We demonstrate that AXL interacts with the DR5/FADD
complex, hence blocking TRAIL-induced activation of caspase-8 and
apoptosis. These novel findings provide strong evidence that AXL
may be exploited as a therapeutic target to sensitize cancer cells to
TRAIL in EAC.
Materials and Methods
Cell Lines and Reagents
The human EAC cancer cell lines, OE33, OE19, and FLO-1, were
a kind gift from Dr David Beer (University of Michigan, Ann Arbor,
MI). The cells were examined weekly to ascertain conformity to the
appropriate in vitro morphologic features [24]. Additionally, the
tumorigenicity of the cells was tested by in vivo tumor growth in female
athymic nude-Foxn 1 nu/nu mice (Harlan Laboratories, Indianapolis,
IN). Human embryonic kidney (HEK-293) cells were obtained from
ATCC (Manassas, VA). These cells were cultured in F12 (HAM) me-
dium (Gibco, Carlsbad, CA) supplemented with 10% FBS (Invitrogen
Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin
(Gibco). Recombinant human TRAIL/Apo2 ligand was obtained from
BioVision Research Products (Mountain View, CA). AXL, DR5,
cleaved caspase-3 and caspase-9, poly (ADP-ribose) polymerase
(PARP), FLIP, Bid, and β-actin antibodies were purchased from Cell
Signaling Technology (Danvers, MA). FADD and DcR1 antibodies
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). DR4
and caspase-8 antibodies were purchased from Abcam (Cambridge, MA)
and Epitomics (Burlingame, CA), respectively. The AXL pharmaco-
logical inhibitor (BMS 777607) was obtained from Selleck Chemicals
LLC (Houston, TX).
AXL Expression and Small Hairpin RNA
The plasmids of pcDNA4/AXL–myc-His and pcDNA4, kindly pro-
vided by Dr Rosa Marina Melillo (University of Naples, Naples, Italy),
were used to a generate stable expression in EAC cells. Briefly, OE33
cells, with low endogenous AXL expression, were stably transfected
using Lipofectamine 2000 (Invitrogen) and selected with 100 μg/ml
Zeocin (Invitrogen) following previously described standard protocols
[25]. The coding sequence of AXL from pcDNA3.1/AXL plasmid was
subcloned into the shuttle vector (pACCMV). The recombinant AXL-
expressing adenovirus was generated by co-transfecting HEK-293 cells
with the shuttle and backbone (pJM17) adenoviral plasmids using the
Calcium Phosphate Transfection Kit (Applied Biological Materials Inc,
Richmond, BC). Lentivirus particles expressing control short hairpin
RNA (shRNA) or a pool of five clones of AXL shRNA were gene-
rated and their specificity validated by Sigma-Aldrich (St Louis,
MO). FLO-1 cells, with high endogenous AXL expression, were trans-
duced with lentivirus particles and selected with 1 μg/ml puromycin
(Invitrogen) for 10 days.
Cell Viability Assay
Cell viability was determined using the CellTiter-Glo Luminescent
Cell Viability Assay Kit (Promega, Madison, WI). Briefly, cells (5 ×
103 per well) were cultured onto a 96-well plate. Approximately 18 hours
after seeding, cells were treated with vehicle or various concentrations
of TRAIL for 5 hours. The luminescence was read on a Microplate
Reader (FLUOstar OPTIMA). All experiments were performed in
triplicates and repeated at least three times.
Apoptosis Assay
OE33 cells stably expressing AXL or pcDNA4 empty vector and
FLO-1 cells transduced with lentivirus particles expressing AXL shRNA
or control shRNA were cultured in 60-mm plates and treated with
TRAIL (40 ng/ml) or vehicle overnight. Cells were harvested and
stained with Annexin V–fluorescein isothiocyanate and propidium
iodide (PI; R&D Systems, Minneapolis, MN). The cells were washed
with phosphate-buffered saline (PBS) and resuspended in binding
buffer and then subjected to fluorescence-activated cell sorting (FACS)
analysis by a flow cytometer (Becton Dickinson, Franklin Lakes, NJ).
Apoptotic cell death was determined by measuring the cell population
that stained positive for Annexin V–fluorescein isothiocyanate and PI.
Quantitative Real-Time Reverse Transcription-Polymerase
Chain Reaction
Total RNA was isolated from cells using an RNeasy Mini Kit
(Qiagen, Valencia, CA). Total RNA (1 μg) was used to synthesize
single-stranded cDNA by an iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA). Quantitative real-time reverse transcription-polymerase
chain reaction (RT-PCR) was performed in triplicate using an iCycler
(Bio-Rad) with a threshold cycle number determined by use of iCycler
software version 3.0. mRNA specific primers for DR5, DR4, and
HPRT1 were designed, and the results were normalized to HPRT1 as
a stable reference gene for quantitative real-time RT-PCR. The relative
mRNA expression levels were calculated according to the formula
2(Et − Rt)/2(Rn − En), as described previously [26].
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Western Blot Analysis
Cell lysates were prepared in RIPA buffer (50 mmol/l Tris-HCl
buffer, pH 7.4, 150 mmol/l NaCl, 1% Triton X-100, 1% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate) supplemented with
1× Halt protease inhibitor cocktail and 1× Halt phosphatase inhibitor
cocktail (Pierce, Rockford, IL). A Bio-Rad protein assay (Bio-Rad)
was used to determine protein concentrations. Proteins were separated
on 10–12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to Protran nitrocellulose membranes (Whatman, Boston,
MA). Membranes were first hybridized with specific primary anti-
bodies and then with HRP-conjugated secondary antibodies (Cell
Signaling Technology). Protein bands were visualized using a commer-
cial Immobilon Western Chemiluminescent HRP Substrate detection
reagent (Millipore, Billerica, MA).
Immunoprecipitation
Cells were solubilized for 30 minutes with ice-cold RIPA buffer
containing 1% Halt protease inhibitor cocktail (Pierce). The cell
lysates were sonicated and spun down at 15,000 rpm for 10 minutes.
Protein concentration in the supernatants was measured by the Bio-
Rad Protein Assay. Using a primary antibody bound to Dynabeads
Protein G (50 μl; Invitrogen), immunoprecipitations of equal total
proteins (200 μg) were performed at room temperature for 1 hour.
The beads were washed with ice-cold PBS and then heated to 100°C
for 5 minutes in sample buffer. The denatured proteins were eluted by
magnet and subjected to Western blot analysis.
Statistical Analysis
The results were expressed as means ± SD. The statistical significance
of the studies was determined by the parametric unpaired Student’s
t test. Differences with P values ≤ .05 are considered significant.
Results
AXL Promotes Survival of EAC Cells
To investigate the role of AXL in cell survival, we generated two esoph-
ageal cell models. We employed OE33 and OE19 cells, with low endog-
enous AXL expression, to stably or transiently overexpress AXL, respectively
(Figure 1, A and C), and FLO-1 cells, with high endogenous AXL pro-
tein level, to stably knockdown AXL expression (Figure 1E). Western
blot analysis data confirmed the expression of exogenous and endoge-
nous AXL proteins as indicated by the full-length protein (138 kDa)
Figure 1. AXL expression enhances survival of EAC cells. (A) OE33 cells were stably transfected with AXL or pcDNA4 control plasmids and
subjected to Western blot analysis of AXL protein. (B) OE33/pcDNA4 and OE33/AXL stable cells were treated with vehicle or with the
indicated concentrations of recombinant TRAIL for 5 hours. Cell viability was evaluated by CellTiter-Glo Luminescent Cell Viability Assay. Cell
survival of AXL-expressing cells was significantly higher than control cells in response to TRAIL. (C) OE19 cells were infected with control
(10 MOI, multiplicity of infection) or AXL (10 MOI) adenoviruses and subjected to Western blot analysis of AXL protein. (D) Cell viability of
OE19 cells transiently expressing control empty vector or AXL in response to TRAIL was evaluated as in B. Survival of cells expressing AXL
was significantly higher than control cells in response to TRAIL. (E) FLO-1 cells were transduced with lentivirus particles expressing AXL
shRNA or control shRNA and subjected toWestern blot analysis of AXL protein. (F) Cell viability of FLO-1 cells stably expressing AXL shRNA
or control shRNA in response to TRAIL was assessed as in B. Knockdown of endogenous AXL in FLO-1 cells significantly decreased cell
survival in response to TRAIL. Results are representative of at least three experiments and shown as means ± SD. *P < .05, **P < .01.
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and the short fragment (55 kDa; Figure 1, A, C , and E). The cell viabil-
ity assay results demonstrated that the reconstitution of AXL expression
in OE33 and OE19 cells significantly enhanced cell survival relative to
control cells in response to treatment with increasing concentrations of
TRAIL for 5 hours (P < .01; Figure 1, B and D). Indeed, the TRAIL
half maximal inhibitory concentration (IC50) in OE33 cells stably
overexpressing AXL (135.6 ng/ml) was significantly higher than control
cells (64.4 ng/ml; Figure 1B). Similarly, the TRAIL half maximal in-
hibitory concentration (IC50) in OE19 cells transiently overexpressing
AXL (178.3 ng/ml) was also significantly higher than control cells
(83 ng/ml; Figure 1D). To corroborate the role of AXL in regulating
cell survival, we subjected FLO-1 cells stably expressing control shRNA
or AXL shRNA to the cell viability assay after treatment with increasing
concentrations of TRAIL for 5 hours. The data unequivocally indicated
that knockdown of endogenous AXL significantly enhanced the sensi-
tivity of cells to TRAIL (P < .05; Figure 1F ). In fact, the TRAIL IC50 in
FLO-1/AXL shRNA cells (58.8 ng/ml) was considerably lower than
FLO-1/control shRNA cells (77.5 ng/ml; Figure 1F ). Of note, we
demonstrated that the pro-survival function of AXL was dependent
on its kinase activity. The cell viability assay data indicated that inhibi-
tion of AXL with the pharmacological compound BMS-777607 signif-
icantly sensitized FLO-1 cells to TRAIL (P < .001; Figure W1).
AXL Attenuates TRAIL-Induced Apoptosis and Activation
of Caspases
To assess the role of AXL in regulating TRAIL-induced apoptosis,
we employed OE33 and FLO-1 cell models. On the basis of the sur-
vival data (Figure 1, B and F), we selected the TRAIL concentration
40 ng/ml to induce apoptosis in cells. The Annexin V/PI staining
and FACS analysis data clearly demonstrated that the reconstitution
of AXL expression in OE33 cells suppressed apoptosis events by
53% relative to control in response to TRAIL (P < .01; Figure 2A).
In accordance with this finding, Western blot analysis showed con-
siderably higher protein levels of cleaved caspase-8, caspase-9, and
caspase-3 and cleaved PARP in control cells than AXL-expressing cells
in response to TRAIL (Figure 2B). On the contrary, the data indicated
that knockdown of highly expressed endogenous AXL in FLO-1 cells
significantly increased apoptosis by 74% relative to control (P = .01)
in response to TRAIL (Figure 2C). In line with this finding, Western
blot analysis indicated that knockdown of endogenous AXL sub-
stantially increased protein levels of cleaved caspase-8, caspase-9, and
caspase-3 and cleaved PARP relative to control in response to TRAIL
(Figure 2D). To confirm that AXL regulates TRAIL-induced activation
of the intrinsic mitochondrial apoptosis pathway, we evaluated cleav-
age of Bid in FLO-1 cells. Western blot data indicated that knock-
down of endogenous AXL significantly enhanced cleavage of Bid in
response to TRAIL (Figure W2).
AXL Does Not Downregulate Differentially Expressed
DR5 and DR4 Death Receptors in EAC Cells
To investigate if AXL mediates TRAIL resistance through down-
regulation of the expression of death receptors, we evaluated mRNA
and protein levels of DR5 and DR4 receptors in OE33 and FLO-1
cell models. Real-time RT-PCR data showed that the reconstitution
of AXL expression and treatment with vehicle or TRAIL induced
approximately a 40% increase in DR5 and DR4 mRNA levels in
OE33 cells (Figure 3A). In addition, the results indicated that knock-
ing down endogenous AXL and treatment with vehicle or TRAIL had
no significant effect on DR5 and induced less than a 10% decrease
in DR4 mRNA expression in FLO-1 cells (Figure 3B). Interestingly,
the data revealed that DR5 and DR4 were consistently differentially
expressed in both OE33 and FLO-1 cells, as mRNA expression of
DR5 was approximately two-fold higher than DR4 relative to HPRT1
(Figure 3, A and B). Western blot data showed that the reconstitution
of AXL expression in OE33 cells induced a slight increase in DR5 and
DR4 protein levels relative to control cells after treatment with vehicle
or TRAIL (Figure 3C ). The data also indicated that knockdown of
endogenous AXL in FLO-1 cells after treatment with vehicle or TRAIL
had no significant effect on DR5 protein expression but slightly de-
creased the DR4 protein level relative to control (Figure 3D). Together,
the data clearly indicated that AXL had no negative regulatory effect on
mRNA and protein expression of DR5 and DR4 receptors in EAC
cells. Moreover, we performed immunofluorescence assays to investi-
gate the role of AXL in regulating DR5 and DR4 localization on the
cell surface. The data indicated that AXL expression has no significant
effect on the expression and localization of these receptors on the cell
surface in OE33 cells (Figure W3A). We also explored the role of AXL
in regulating the decoy death receptor DcR1 protein expression in
OE33 cells. Western blot data showed that AXL expression has no
effect on DcR1 protein level (Figure W3B).
AXL Associates with DISC and Prevents TRAIL-Induced
Caspase-8 Interaction
On the basis of our finding that DR5 mRNA expression was con-
siderably higher than DR4 in EAC cells (Figure 3), we decided to
focus on DR5 death receptor in our study to investigate the molecular
mechanism by which AXL promotes TRAIL resistance. After excluding
down regulation of the expression of death receptors (Figure 3) as a
mechanism of AXL-mediated TRAIL resistance, we next postulated
that AXL regulates DISC, thereby blocking TRAIL-induced apoptosis
signaling in EAC cells. Indeed, reciprocal immunoprecipitation and
Western blot data indicated that AXL associated with DR5, a com-
ponent of DISC, independent of TRAIL treatment in OE33 cells
(Figure 4, A and B). Of note, the short fragment of AXL (55 kDa)
appeared to interact relatively more efficiently than the full-length
AXL (138 kDa) with DR5 (Figure 4A). Furthermore, we investigated
whether AXL/DR5 protein association could interfere with the recruit-
ment of FADD in response to TRAIL in OE33 cells. Western blot
analysis of FADD immunoprecipitates clearly showed that AXL/DR5
association had no effect on FADD interaction with DR5 in response
to TRAIL (Figure 5A). This finding suggested that AXL-mediated
TRAIL resistance mechanism could be downstream of the DR5/
FADD protein complex. Accordingly, we next examined if AXL/
DR5/FADD protein interaction could block the recruitment of the
pro-form of caspase-8 in response to TRAIL. This step is critical for
activation of caspase-8 and initiation of TRAIL-induced extrinsic
apoptotic signaling cascade. The immunoprecipitation andWestern blot
data clearly indicated significantly less interaction of pro-caspase-8 with
the DR5/FADD complex in response to TRAIL in AXL-expressing
OE33 cells than control cells (Figure 5A). Interestingly, in addition to
pro-caspase-8, cleaved forms of caspase-8 also interacted with the pro-
tein complex (Figure 5A).We validated these data in a FLO-1 cell model
by knocking down endogenous AXL and examining the formation of
DISC in response to TRAIL. Western blot analysis of FADD immuno-
precipitates showed that knocking down AXL had no effect on DR5/
FADD association but significantly increased the recruitment of pro-
caspase-8 by FADD in response to TRAIL (Figure 5B). Similar to
OE33 cells, in addition to pro-caspase-8, cleaved forms of caspase-8 also
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associated with the DISC protein complex in FLO-1 cells (Figure 5B).
Together, these data demonstrated a novel mechanism of TRAIL re-
sistance by which AXL regulates the DISC through interaction with
DR5 and FADD, thereby blocking the recruitment and activation of
caspase-8, a key molecular event in TRAIL-induced apoptosis.
An alternative mechanism of TRAIL resistance could involve reg-
ulation of FLIP, which resembles caspase-8 but lacks the enzymatic
activity and competes with caspase-8 to bind to FADD, hence inhib-
iting TRAIL-induced apoptosis. Western blot analysis data showed
that the reconstitution of AXL expression in OE33 cells and treat-
ment with vehicle or TRAIL had no significant effect on FLIP pro-
tein levels (Figure W4A). In addition, we investigated whether AXL
could regulate the interaction of FLIP with FADD in response to
TRAIL in OE33 cells. The immunoprecipitation and Western blot
data showed that AXL did not enhance the recruitment of FLIP by
FADD but rather reduced FLIP/FADD association in response to
Figure 2. AXL expression attenuates TRAIL-induced apoptosis. (A) OE33/pcDNA4 and OE33/AXL stable cells were treated with vehicle
or TRAIL (40 ng/ml) for 24 hours. Apoptosis was determined by Annexin V/PI staining and FACS analysis. Quantitative data indicated sig-
nificantly less apoptosis in AXL-expressing cells than control cells (P< .01) in response to TRAIL. (B) Immunoblot analysis of AXL, caspase-8,
cleaved caspase-9 and caspase-3, and PARP proteins in OE33/pcDNA4 and OE33/AXL cells after treatment with vehicle or TRAIL as de-
scribed in A. (C) Apoptosis in FLO-1/control shRNA and FLO-1/AXL shRNA cells after treatment with TRAIL (40 ng/ml) for 24 hours was
assessed as in A. Quantitative data showed that knocking down endogenous AXL induced significantly more apoptosis than control cells
(P = .01) in response to TRAIL. (D) Western blot analysis of AXL, caspase-8, cleaved caspase-9, cleaved caspase-3, and PARP proteins
in FLO-1/control shRNA and FLO-1/AXL shRNA cells after treatment with TRAIL as in C. Gel loadingwas normalized for equal β-actin. Results
are representative of at least three experiments.
300 AXL Mediates TRAIL Resistance Hong and Belkhiri Neoplasia Vol. 15, No. 3, 2013
Figure 3. DR5 and DR4 death receptors are differentially expressed but not downregulated by AXL in EAC cells. (A) OE33/pcDNA4 and
OE33/AXL cells were treated with vehicle or TRAIL (40 ng/ml) for 5 hours. Real-time RT-PCR analysis indicated that AXL expression alone
or in combination with TRAIL induced a 40% increase in mRNA expression of DR5 and DR4 receptors. However, the mRNA expression of
DR5 was approximately two-fold higher than DR4 relative to HPRT1 in OE33 cells. (B) FLO-1/control shRNA and FLO-1/AXL shRNA cells
were treated as in A. Knocking down AXL alone or in combination with TRAIL had no significant effect on DR5 but induced a less than 10%
decrease in DR4 mRNA expression. Similar to OE33 cells, FLO-1 cells expressed approximately two-fold higher mRNA level of DR5 than
DR4 relative to HPRT1. (C) OE33/pcDNA4 and OE33/AXL cells were treated as in A. Western blot analysis indicated that AXL expression
alone or in combination with TRAIL slightly increased protein levels of DR5 and DR4 in OE33 cells. (D) FLO-1/control shRNA and FLO-1/AXL
shRNA cells were treated as in A. Western blot analysis showed that knocking down AXL alone or in combination with TRAIL had no sig-
nificant effect on DR5 protein expression but slightly decreased DR4 protein level. Gel loading was normalized for equal β-actin.
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TRAIL (Figure W4B). These findings clearly demonstrated that
AXL-mediated TRAIL resistance did not involve regulation of FLIP.
Discussion
The therapeutic strategies for advanced EAC involve surgery, platinum-
based therapy, and radiotherapy, which are ineffective and frequently
associated with poor outcome [5]. The fact that the majority of EAC
are deficient or mutant in p53, which is critical for mediating the
apoptotic response to DNA-damaging therapies [27,28], underscores
the need for alternative therapeutic approaches. Better knowledge of
the molecular basis of cell growth and apoptosis of cancer cells is
paramount for the development of novel targeted anticancer therapies.
Accordingly, direct induction of death receptor-mediated apoptosis
by recombinant proteins, such as TRAIL or DR4/DR5 agonistic
monoclonal antibodies, has been evaluated in clinical trials. Overall,
the clinical data indicated promising antitumor growth activities with
mild side effects (reviewed by Kruyt [29]). However, it has become
evident that intrinsic and acquired resistance to TRAIL remains a major
clinical challenge [15]. Elucidation of the molecular mechanisms that
control TRAIL resistance is critical to predicting response to therapy
and to developing new therapeutic approaches that can overcome resis-
tance. On the basis of the reported findings of frequent overexpression
of AXL in EAC and its association with the multistep esophageal car-
cinogenesis [22,23] and the implication of AXL in promoting cell
survival in various malignancies [17,18,23], we examined the role of
AXL in TRAIL resistance in EAC.
Our findings demonstrated that AXL enhanced cell survival and
inhibited apoptosis in response to TRAIL, confirming an important
role of AXL in TRAIL resistance in EAC. Of note, we showed that
the pro-survival function of AXL was dependent on its kinase activity.
To examine the effects of AXL on the molecular signaling of apoptosis,
we clearly showed that the reconstitution of AXL expression blocked
TRAIL-induced activation of caspase-8, caspase-9, and caspase-3 and
cleavage of PARP. Conversely, knockdown of endogenous AXL con-
siderably sensitized cells to TRAIL as indicated by increased activation
of caspase-8, caspase-9, and caspase-3 and cleavage of PARP. Upon
binding to DR4 or DR5 death receptors, TRAIL induces the formation
of DISC through interaction with FADD and the recruitment and
activation of caspase-8, thereby inducing the extrinsic apoptosis path-
way [6,7]. The activated caspase-8 can directly cleave and activate
caspase-3 leading to apoptosis in type I cells. Additionally, it can induce
the intrinsic mitochondrial apoptosis pathway through cleavage of Bid
and activation of caspase-9 and caspase-3 in type II cells [8,9]. In fact,
we confirmed that AXL regulated TRAIL-induced activation of the
intrinsic apoptosis pathway in FLO-1 cells. We demonstrated that
knockdown of endogenous AXL significantly enhanced cleavage of
Bid in response to TRAIL. Our data indicated that OE33 and FLO-1
cell models used in this study correspond to type II cells.
In an attempt to identify the molecular mechanism by which
AXL mediates TRAIL resistance, we investigated whether AXL down-
regulates the expression of death receptors in EAC cells. Loss of ex-
pression or elevated endocytic down regulation of death receptors has
been shown to induce TRAIL resistance in cancer cells [30,31]. Our
data indicated that the AXL-mediated TRAIL resistance mechanism
does not involve down regulation of death receptors. Therefore, we
postulated that AXL associates with DR5 and blocks its activation in
response to TRAIL in EAC cells. Indeed, our results demonstrated
AXL/DR5 protein interaction independent of TRAIL treatment. Inter-
estingly, the full-length AXL (138 kDa) associated significantly less
than the short form of AXL (55 kDa) with the DR5 receptor, although
the protein expression level of AXL short form was considerably lower
than the full-length. Together with the full-length, the AXL short form
was consistently expressed endogenously and ectopically in EAC cells.
Moreover, it is likely that the AXL short form was generated by pro-
teolytic degradation of the full-length protein through cleavage and
shedding of the extracellular domain. Our data confirmed that the
AXL short form protein consists of the cytosolic domain as it was
detected by immunoblot analysis using an antibody directed against
the intracellular portion of AXL. Consistent with our finding, a pre-
vious study indicated that AXL is proteolytically cleaved at the cell
surface immediately NH2-terminal to the transmembrane domain pro-
ducing a soluble extracellular domain (80 kDa) and an intracellular
membrane-bound kinase domain (55 kDa) [32]. The increased affinity
Figure 4. AXL associates with DR5 in a protein complex. (A) Western blot analysis of immunoprecipitated proteins with control IgG or DR5
antibodies in OE33 cells stably expressing AXL without treatment with TRAIL. (B) Western blot analysis of control IgG or AXL immuno-
precipitates in OE33 cells stably expressing AXL without TRAIL treatment. The reciprocal co-immunoprecipitation results demonstrated
protein association of AXL with DR5 death receptor independent of TRAIL-induced apoptosis; *, non-specific protein band.
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of AXL short form to bind DR5 relative to the full-length suggests that
the stoichiometry and composition of this protein interaction could
play a major role in TRAIL resistance. Additional studies will be re-
quired to test this hypothesis. Although we focused our investigation
on DR5, we also checked if AXL could similarly interact with DR4.
The immunoprecipitation and Western blot data showed that AXL
associated with DR4 receptor (Figure W5).
We next investigated if AXL could interfere with the interaction of
DR5 with the adaptor protein FADD in response to TRAIL. Our results
showed that AXL association withDR5 had no effect on TRAIL-induced
interaction of FADD with DR5, suggesting that DR5 ligand binding
and DR5 clustering were not hindered by AXL. On the contrary, pre-
vious reports indicated that Met, a growth factor receptor tyrosine kinase
(RTK), directly binds and sequesters the death receptor Fas, preventing its
self-aggregation, Fas ligation, and apoptosis in hepatocytes and endo-
thelial cells [33,34]. On the basis of our findings, we hypothesized that
AXL could regulate DISC formation through blocking the recruitment
of pro-caspase-8 by FADD, hence preventing activation of caspase-8
and apoptosis in response to TRAIL. Indeed, we confirmed that AXL
association with DR5 and FADD significantly reduced the recruitment
of pro-caspase-8 to the DISC. Conversely, we demonstrated that knock-
ing down endogenous AXL enhanced the recruitment of pro-caspase-8
to the DISC and increased TRAIL-induced apoptosis. Up-regulation
of the endogenous FLIP is reported to function by competing with
pro-caspase-8 for binding to DISC, thereby inhibiting apoptosis in re-
sponse to TRAIL [14]. We demonstrated that AXL did not significantly
enhance FLIP expression but rather decreased FLIP/FADD interaction
in EAC cells, indicating that AXL-dependent attenuation of the recruit-
ment of pro-caspase-8 to the DISC was independent of FLIP.
The fact that AXL/DR5 association was independent of TRAIL sug-
gested that this protein interaction could potentiate AXL-expressing
cells for resistance against TRAIL. Although AXL had no effect on
the binding of activated DR5 to FADD through death domain, it sig-
nificantly reduced caspase-8/FADD protein association through death
effector domain. It is likely that the presence of AXL in the DISC could
affect the protein conformation of the complex such that the death
effector domain of FADD is not accessible for pro-caspase-8. Addi-
tional studies will be required to fully characterize the exact mechanism
by which AXL regulates these protein interactions. This is the first
instance, to the best of our knowledge, where an RTK association with
DR5 death receptor is reported to mediate TRAIL resistance in cancer
cells. In conclusion, our findings demonstrate that AXL promotes
TRAIL resistance through binding to DR5 and regulation of the
DISC in EAC cells. Together, our data provide strong evidence that
AXL could be exploited as a therapeutic target to sensitize tumors to
recombinant TRAIL in EAC.
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Supplemental Materials and Methods
Immunofluorescence
Cells (5 × 103 per chamber) were seeded on eight-chamber culture
slides (BD Falcon, Franklin Lakes, NJ) 1 day before the experiment.
Cells were fixed with 4% formaldehyde in PBS for 20 minutes at room
temperature followed by permeabilization with 0.1% sodium citrate
plus 0.1% Triton X-100. Immunofluorescence was performed with
both DR5 (1:500) and DR4 (1:500) antibodies. The cells were then
washed with cold PBS three times for 3 minutes each and incubated
with Alexa 488-labeled anti-rabbit antibody (1:800; Invitrogen) at
room temperature for 1 hour. The cells were counterstained with
4′,6-diamidino-2-phenylindole and examined by fluorescence micros-
copy (Olympus America Inc, Center Valley, PA).
Figure W2. Knockdown of endogenous AXL enhances TRAIL-
induced cleavage of Bid. FLO-1 cells stably expressing control shRNA
or AXL shRNA were treated with vehicle or TRAIL (40 ng/ml) for
5 hours and then subjected to Western blot analysis of AXL and Bid
proteins. The data indicated that knockdown of AXL expression sig-
nificantly increased cleavage of Bid in response to TRAIL. Gel loading
was normalized for equal β-actin.
Figure W1. Biochemical inhibition of endogenous AXL sensitizes
cells to TRAIL. FLO-1 cells were treated with vehicle, AXL inhibitor
(BMS-777607, 5 μM), TRAIL (40 ng/ml) alone or in combination
with BMS-777607 for 5 hours. Cell viability was evaluated by CellTiter-
Glo Luminescent Cell Viability Assay. Inhibition of AXL with BMS-
777607 significantly decreased cell survival in response to TRAIL
(P < .001).
Figure W3. AXL has no significant effect on expression and localization of death receptors. (A) OE33 cells stably expressing pcDNA4 or AXL
were subjected to immunofluorescence with DR5 or DR4 antibodies. Cells were then counterstained with 4′,6-diamidino-2-phenylindole
(blue fluorescence) and examined by fluorescence microscopy. The data indicated that the reconstitution of AXL had no significant effect
on expression and localization (green fluorescence) of DR5 and DR4 death receptors. Representative 40×magnification images are shown.
(B) Western blot analysis of AXL and DcR1 proteins in OE33 cells stably expressing pcDNA4 or AXL. The data indicated that the recon-
stitution of AXL had no effect on DcR1 protein expression. Gel loading was normalized for equal β-actin.
Figure W4. AXL has no significant positive effect on FLIP expression or FLIP/FADD protein association. (A) OE33 cells stably expressing
pcDNA4 or AXL were treated with vehicle or TRAIL (40 ng/ml) for 5 hours and then subjected to Western blot analysis of AXL and FLIP
proteins. The data indicated that AXL expression alone or in combination with TRAIL had no significant effect on FLIP protein levels.
(B) Western blot analysis of control IgG or FLIP immunoprecipitates in OE33/pcDNA4 or OE33/AXL cells following treatment with TRAIL
(40 ng/ml) for 5 hours. The data showed that the reconstitution of AXL in OE33 cells reduced FLIP/FADD interaction in response to TRAIL; *,
non-specific protein band. Gel loading was normalized for equal β-actin.
Figure W5. AXL and DR4 are associated in a protein complex.
Western blot analysis of immunoprecipitated proteins with control
IgG or DR4 antibodies in OE33 cells stably expressing AXL without
treatmentwithTRAIL. Thedata indicatedprotein interactionbetween
AXL and DR4 independent of TRAIL.
